Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21219011 | 1.00 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL4462266 | 0.85 | KDR (0.45) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL2598085 | 0.84 | KDR (0.44) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL2597970 | 0.83 | KDR (0.44) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL3969025 | 0.82 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL3974927 | 0.79 | KDR (0.43) | CYP3A4KDRDAO | |
| SCHEMBL28413554 | 0.78 | PPARA (0.62) | KDRDAO | |
| SCHEMBL6781413 | 0.78 | KDR (0.52) | CYP1A2CYP3A4CYP2D6KDRDAO | |
| SCHEMBL18551815 | 0.78 | MAOA (0.51) | CYP1A2CYP2D6KDRDAO | |
| SCHEMBL3969847 | 0.77 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109316601-B | Pharmaceutical composition and use thereof | 武汉朗来科技发展有限公司 | 2021-11-09 | — | — | CN | disclosed |
| EP-2571843-B1 | IMPROVED PREPARATION OF CHALCONE DERIVATIVES | GENFIT (FR) | 2017-12-27 | — | — | EP | disclosed |
| US-8765992-B2 | Preparation of chalcone derivatives | GENFIT (FR) | 2014-07-01 | — | — | US | disclosed |
| US-8461212-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20130131372-A1 | PREPARATION OF CHALCONE DERIVATIVES | GENFIT (FR) | 2013-05-23 | — | — | US | disclosed |
| EP-2571843-A1 | IMPROVED PREPARATION OF CHALCONE DERIVATIVES | Genfit (FR) | 2013-03-27 | — | — | EP | disclosed |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2012-05-24 | — | — | US | disclosed |
| US-8106097-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2012-01-31 | — | — | US | disclosed |
| WO-2011144579-A1 | IMPROVED PREPARATION OF CHALCONE DERIVATIVES | GENFIT (FR) | 2011-11-24 | — | — | WO | disclosed |
| US-8058308-B2 | Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2011-11-15 | — | — | US | disclosed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20060142611-A1 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | GENFIT (FR) | 2006-06-29 | — | — | US | disclosed |
| EP-1644312-A1 | PREPARATION OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | Genfit (FR) | 2006-04-12 | — | — | EP | disclosed |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | GENFIT (FR) | 2005-08-11 | — | — | US | disclosed |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2005-08-04 | — | — | US | disclosed |
| EP-1525177-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-27 | — | — | EP | disclosed |
| EP-1519908-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-06 | — | — | EP | disclosed |
| WO-2005005369-A1 | PREPARATION OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004005243-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004005233-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | GENFIT (FR) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | CYP1A2 1583/4885CYP3A4 3088/4885CYP2D6 2461/4885 |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | BRCA1, COL1A1, APOL1 | CYP1A2 1330/4885CYP3A4 3511/4885CYP2D6 1913/4885 |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | PGF, PTGS1, PTGES3 | CYP1A2 1038/4885CYP3A4 1522/4885CYP2D6 998/4885 |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | BRCA1, LOXL1, APOL1 | CYP1A2 1532/4885CYP3A4 3581/4885CYP2D6 1879/4885 |
| US-20060142611-A1 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | DPEP1, PKD1, ENPP1 | CYP1A2 957/4885CYP3A4 1149/4885CYP2D6 403/4885 |
| US-20130131372-A1 | PREPARATION OF CHALCONE DERIVATIVES | SULT1E1, HCCS, STS | CYP1A2 288/4885CYP3A4 201/4885CYP2D6 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.